Globus Medical Is Cheap For A Reason: The Nevro Stall Hasn't Been Resolved

# Globus Medical Is Cheap For A Reason: The Nevro Stall Hasn't Been Resolved

Let's get the obvious out of the way: Globus Medical looks cheap. Trailing P/E hovering in the high teens while the medical-device peer group trades near 41x. A balance sheet with $595 million in cash against $112 million in debt. Free cash flow north of half a billion. And a Q2 that beat on both the top and bottom line. Any screener will hand you this story with a grin.

Now let's talk about why the stock has fallen roughly 13% from where the last read had it, and why "cheap" is doing a lot of heavy lifting here.

The Q2 2026 report — released August 6, already six weeks in the rearview — was genuinely mixed, and the market has been pricing that mix ever since. Revenue of $789.6 million, up about 6% reported and a respectable 9% organic excluding Nevro. GAAP EPS of $1.34 against $1.12 expected. Adjusted EBITDA margin at a glistening 35.4%, up 740 basis points year-over-year. On paper that's the bull thesis in a nutshell: pricing power, operational leverage, a company that can grow margins even while buying something.

But net income fell — to $151.57 million from $202.85 million a year earlier. That's not a rounding error. That's a profitability squeeze disguised as a beat. And there's a reason it happened that the margin headline tries to bury: the Nevro integration is stalling.

Here's the crux of the whole position. Management told investors that Q2 Nevro sales were "essentially flat to Q1." They framed cross-sell and pull-through as a future catalyst. Translation: the deal was bought on the promise that you could sell Nevro's neuromodulation products through Globus's spine channel — and so far the combined machine isn't turning faster. Revenue is up, EPS beat, the EBITDA line is pretty. But the entire thesis for buying GMED at a discount rather than at a premium is the synergy play, and the synergy play is showing cracks right where it matters.

So where does that leave us?

The bulls have real material to defend. The company generates roughly $910 million in operating cash flow, holds a fortress current ratio, and reinvests heavily — ExcelsiusGPS robotics adoption is the genuine growth engine in the core business, not Nevro, which is currently a drag. And the valuation is, again, not crazy. A forward P/E near 13.8x with a PEG around 1.0 for a device company with these margins is a genuine gap.

But "value zone" isn't a synonym for "buy now," and I want to be blunt about the technicals, because they're not flattering. The name has tumbled out of the $96+ range down toward the mid-$70s, trading below its 20-day, 50-day, and 200-day moving averages. RSI in the high 30s — approaching oversold, yes, but that's a condition, not a signal. The trend across every timeframe is down. Support near $64–65 exists for a reason; the 52-week low of $54.15 is the floor nobody wants to talk about. And insiders sold — two director sells of $2.2 million each in mid-August and mid-September. You don't get a cleaner "management isn't convinced" read if you tried.

And then there's the calendar, which does most of the work for or against this idea. Next earnings lands around November 5 — roughly six weeks out — and it's a binary event on an integration story that hasn't proven itself. That's not noise. That's the entire plot. The model's own one-day directional accuracy is roughly 39%, which is worse than a coin flip and worse than the naive baseline, so anyone treating a near-term forecast band as gospel is reading tea leaves. The one-week accuracy is stronger at 83%, which at least suggests the mid-$60s could act as a floor rather than a launchpad to the downside — if the tape holds.

My read? This is a patience and sizing stock, not a conviction add. The fundamentals aren't broken — the margins, the cash, the balance sheet are all intact and, frankly, impressive. But the one thing that justifies owning it over a cheaper, higher-growth peer is the Nevro synergy, and that synergy is flat. Until Q3 shows combined sales actually accelerating — until the cross-sell thesis produces a line in the sand instead of a line on a call — "cheap" is just a description, not a thesis.

I'd rather accumulate toward that $64–65 support with a plan than chase a dead-cat bounce below every moving average. The catalyst is close enough to matter and far enough to let the story breathe. Buy the story when it shows you the story, not before.

Cheap stocks don't get cheaper forever. They get cheaper because something's wrong. In GMED's case, something's merely delayed — which is forgivable, if you have the stomach to wait for it to resolve.